Article

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma

2023-12-04

Abstract excerpt

<h4>Summary</h4> Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations. However, the impact of inhibiting RAS functions in normal tissues is not known. RMC-7977 is a highly selective inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants. As >90% of human...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e6f89c8b-b56a-5976-9b71-4c1d780ec53c
DOI: 10.1101/2023.12.03.569791

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaDOI 10.1101/2023.12.03.569791Read

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.Semantic proximity Read

A TARGETED COMBINATION THERAPY ACHIEVES EFFECTIVE PANCREATIC CANCER REGRESSION AND PREVENTS TUMOR RESISTANCESemantic proximity Read

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.Semantic proximity Read

Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors.Semantic proximity Read

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaSemantic proximity Read

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.Semantic proximity Read

Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts.Semantic proximity Read

PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSemantic proximity Read

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.Semantic proximity Read

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read